FILE 'USPAT' ENTERED AT 11:24:11 ON 02 JUN 1998

=> s ((tumor? or tumour?)(w)(necros?
factor?))(5a)receptor?

22089 TUMOR?
2061 TUMOUR?
7120 NECROS?
413965 FACTOR?
2191 NECROS? FACTOR?
(NECROS?(W)FACTOR?)
32151 RECEPTOR?
L1 113 ((TUMOR? OR
TUMOUR?)(W)(NECROS? FACTOR?))(5A)RECEPTOR?

=> s l1 and (DNA? or cDNA? or rna? or mRNA? or clon?)

24790 DNA? 8581 CDNA? 14544 RNA? 7557 MRNA? 20589 CLON?

L2 109 L1 AND (DNA? OR CDNA? OR RNA? OR MRNA? OR CLON?)

=> d 1-20

- 1. 5,756,291, May 26, 1998, Aptamers specific for biomolecules and methods of making; Linda Griffin, et al., 435/6; 530/413; 536/23.1; 935/77, 78 [IMAGE AVAILABLE]
- 2. 5,753,628, May 19, 1998, Peptide inhibitors of TNF containing predominantly D-amino acids; George A. Heavner, et al., 514/17, 12, 13, 14, 15, 16, 18; 530/324, 325, 326, 327, 328, 329, 330 [IMAGE AVAILABLE]
- 3. 5,753,620, May 19, 1998, Human therapeutic uses of BPI protein products; Nadav Friedmann, et al., 514/12; 424/85.1, 85.2, 529, 534; 514/21, 921; 530/324, 350, 351, 830 [IMAGE AVAILABLE]
- 4. 5,753,462, May 19, 1998, Secretion leader trap **cloning** method; Si Lok, 435/69.1, 172.3; 536/23.1 [IMAGE AVAILABLE]
- 5. 5,753,225, May 19, 1998, Antibodies that mimic actions of neurotrophins; Douglas O. Clary, et al., 424/130.1, 141.1, 143.1, 156.1; 530/387.1, 388.1, 388.22 [IMAGE AVAILABLE]
- 6. 5,750,653, May 12, 1998, Protein, FAF1, which potentiates

Fas-mediated apoptosis and uses thereof; Keting Chu, et al., 530/350; 435/7.1, 69.7 [IMAGE AVAILABLE]

- 7. 5,747,292, May 5, 1998, Chimeric cytokine receptors in lymphocytes; Philip D. Greenberg, et al., 435/69.7, 252.3, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]
- 8. 5,747,245, May 5, 1998, Nucleic acids encoding Fas associated proteins and screening assays using same; John C. Reed, et al., 435/6, 91.2; 536/23.1, 24.3, 24.33 [IMAGE AVAILABLE]
- 9. 5,744,304, Apr. 28, 1998, Inflammation-induced expression of a recombinant gene; Robert S. Munford, 435/6, 69.1, 172.3; 514/44 [IMAGE AVAILABLE]
- 10. 5,741,667, Apr. 21, 1998, Tumor necrosis factor receptor-associated factors; David V. Goeddel, et al., 435/69.1, 252.3, 320.1; 536/23.5 [IMAGE AVAILABLE]
- 11. 5,739,300, Apr. 14, 1998, Antiadhesive piperidine-and pyrrolidinecarboxylic acids; Alexander Toepfer, et al., 536/4.1, 18.5, 120, 123 [IMAGE AVAILABLE]
- 12. 5,733,572, Mar. 31, 1998, Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles; Evan C. Unger, et al., 424/450, 1.21, 9.321, 9.4, 489; 436/829 [IMAGE AVAILABLE]
- 13. 5,728,803, Mar. 17, 1998, Pantropic neurotrophic factors; Roman Urfer, et al., 530/350, 399 [IMAGE AVAILABLE]
- 14. 5,725,856, Mar. 10, 1998, Monoclonal antibodies directed to the HER2 receptor; Robert M. Hudziak, et al., 424/130.1, 138.1, 143.1, 156.1, 178.1; 530/387.7, 388.85, 391.3, 391.7 [IMAGE AVAILABLE]
- 15. 5,723,332, Mar. 3, 1998, Translational enhancer **DNA**; Yuti Luis Alberto Chernajovsky, 435/320.1; 536/23.1, 24.1 [IMAGE AVAILABLE]
- 16. 5,723,290, Mar. 3, 1998, Methods for profiling mRNA expression in neurites; James Eberwine, et al., 435/6, 91.2, 91.21, 91.51; 536/23.5, 24.31; 935/17, 18, 77, 78 [IMAGE AVAILABLE]
- 17. 5,723,116, Mar. 3, 1998, Decreased mortality of severe acute pancreatitis following proximal cytokine blockade; James G. Norman, Jr., 424/85.1, 85.2; 514/8, 12, 21; 530/324, 351 [IMAGE AVAILABLE]
- 18. 5,721,121, Feb. 24, 1998, Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin

chimeric protein; Tina Etcheverry, et al., 435/69.7, 325, 328, 358, 361; 530/387.3, 395 [IMAGE AVAILABLE]

- 19. 5,720,954, Feb. 24, 1998, Monoclonal antibodies directed to the HER2 receptor; Robert M. Hudziak, et al., 424/130.1, 85.1, 138.1, 143.1, 156.1, 178.1, 198.1; 530/387.7, 388.85, 391.3, 391.7 [IMAGE AVAILABLE]
- 20. 5,720,937, Feb. 24, 1998, In vivo tumor detection assay; Robert M. Hudziak, et al., 424/9.34; 435/7.23, 40.52; 436/504; 530/387.7, 388.8 [IMAGE AVAILABLE]

=> d 21-40

- 21. 5,716,946, Feb. 10, 1998, Multiple sclerosis treatment; Hector F. DeLuca, et al., 514/167 [IMAGE AVAILABLE]
- 22. 5,716,805, Feb. 10, 1998, Methods of preparing soluble, oligomeric proteins; Subhashini Srinivasan, et al., 435/69.1, 7.2, 69.7, 70.1, 71.1, 172.3, 252.3, 320.1, 325; 530/350; 536/23.1, 23.5 [IMAGE AVAILABLE]
- 23. 5,712,381, Jan. 27, 1998, MADD, a TNF receptor death domain ligand protein; Lih-Ling Lin, et al., 536/23.5; 435/69.1, 70.1, 320.1, 325; 530/300, 350 [IMAGE AVAILABLE]
- 24. 5,712,155, Jan. 27, 1998, DNA encoding tumor necrosis factor-, alpha, and -, beta, receptors: Craig

factor-.alpha. and -.beta. receptors; Craig
A. Smith, et al.,
435/320.1; 424/85.1; 435/69.3, 69.5; 530/351,
388.23, 389.2; 536/23.1;
935/12 [IMAGE AVAILABLE]

- 25. 5,712,115, Jan. 27, 1998, Human cell death-associated protein; Phillip R. Hawkins, et al., 435/69.1, 320.1, 326; 536/23.5; 935/22, 66 [IMAGE AVAILABLE]
- 26. 5,710,013, Jan. 20, 1998, Tumor necrosis factor receptor associated factor 6 (TRAF6); David

V. Goeddel, et al., 435/29, 4, 6, 69.1; 536/23.1, 23.5, 24.3, 24.31, 24.33 [IMAGE AVAILABLE]

27. 5,708,142, Jan. 13, 1998, **Tumor necrosis** factor

receptor-associated factors; David V.
Goeddel, et al., 530/350;
435/69.1, 252.3, 320.1; 536/23.5 [IMAGE
AVAILABLE]

- 28. 5,705,615, Jan. 6, 1998, Antibodies specific for HT.sub.m4; Bing Lim, et al., 530/387.9, 388.23, 389.6 [IMAGE AVAILABLE]
- 29. 5,705,364, Jan. 6, 1998, Mammalian cell culture process; Tina Etcheverry, et al., 435/70.3, 375, 383, 395 [IMAGE AVAILABLE]

- 30. 5,705,349, Jan. 6, 1998, Methods for preparing polynucleotides encoding orphan receptor ligands; Richard D. Holly, et al., 435/7.2, 6, 7.21, 69.1, 69.5, 172.1, 372, 372.1, 405; 436/501; 536/23.1, 23.5 [IMAGE AVAILABLE]
- 31. 5,686,409, Nov. 11, 1997, Antirestenosis protein; D. Grant McFadden, et al., 514/12; 604/53, 265, 266, 269 [IMAGE AVAILABLE]
- 32. 5,684,222, Nov. 4, 1997, Mutant mouse having a disrupted TNFRp55;
 Tak W. Mak, 800/2; 424/9.2; 435/172.3;
 800/DIG.1, DIG.2 [IMAGE AVAILABLE]
- 33. 5,684,136, Nov. 4, 1997, Chimeric hepatocyte growth factor (HGF) ligand variants; Paul J. Godowski, 530/399, 387.3 [IMAGE AVAILABLE]
- 34. 5,677,171, Oct. 14, 1997, Monoclonal antibodies directed to the HER2 receptor; Robert M. Hudziak, et al., 435/7.23, 172.2, 334; 530/387.7, 388.8, 388.85 [IMAGE AVAILABLE]
- 35. 5,674,734, Oct. 7, 1997, Cell death protein; Philip Leder, et al., 435/252.3, 69.1, 69.9, 183; 530/350; 536/23.1, 23.4, 23.5 [IMAGE AVAILABLE]
- 36. 5,674,704, Oct. 7, 1997, Cytokine designated 4-IBB ligand; Raymond G. Goodwin, et al., 435/69.1, 320.1; 530/350; 536/23.5 [IMAGE AVAILABLE]
- 37. 5,674,492, Oct. 7, 1997, Method of preventing or treating disease characterized by neoplastic cells expressing CD40; Richard J. Armitage, et al., 424/144.1, 143.1, 153.1, 154.1, 155.1, 172.1, 173.1, 174.1; 514/2, 8 [IMAGE AVAILABLE]
- 38. 5,670,319, Sep. 23, 1997, Assay for tumor necrosis factor receptor—associated factors; David V. Goeddel, et al., 435/6, 7.1, 7.2, 69.7, 172.3; 536/23.4 [IMAGE AVAILABLE]
- 39. 5,670,149, Sep. 23, 1997, Lymphotoxin-beta., Lymphotoxin-beta. complexes, pharmaceutical preparations and therapeutic uses thereof; Jeffrey Browning, et al., 424/130.1, 133.1, 139.1, 141.1, 142.1, 145.1, 158.1; 435/69.5; 530/388.22, 388.24 [IMAGE AVAILABLE]
- 40. 5,665,859, Sep. 9, 1997, Molecules influencing the shedding of the TNF receptor, their preparation and their use; David Wallach, et al., 530/328; 435/69.2, 226; 530/327, 350 [IMAGE AVAILABLE]

=> d 41-50

41. 5,663,070, Sep. 2, 1997, Recombinant production of a soluble splice
•
variant of the Fas (Apo-1) antigen, fas TM;
Philip J. Barr, et al.,
435/325, 69.1, 253.3, 254.11, 320.1, 348,
358, 361; 536/23.5 [IMAGE
AVAILABLE]

- 42. 5,661,004, Aug. 26, 1997, Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof; Jeffrey Browning, et al., 435/69.1, 325, 358, 366, 372.3; 536/23.5 [IMAGE AVAILABLE]
- 43. 5,658,949, Aug. 19, 1997, Inhibition of tumor necrosis factor by retinoic acid; Bharat B. Aggarwal, 514/557, 825, 895, 903 [IMAGE AVAILABLE]
- 44. 5,654,407, Aug. 5, 1997, Human anti-TNF antibodies; Petra Boyle, et al., 530/388.15; 424/142.1, 145.1, 158.1; 435/335; 530/388.23, 388.24 [IMAGE AVAILABLE]
- 45. 5,652,353, Jul. 29, 1997, DNAs encoding tumor necrosis factor-.alpha. muteins; Walter Fiers, et al., 536/23.5; 435/69.5, 172.3, 252.3, 320.1; 935/11, 22, 70, 73 [IMAGE AVAILABLE 1
- 46. 5,652,225, Jul. 29, 1997, Methods and products for nucleic acid delivery; Jeffrey M. Isner, 514/44; 424/93.2; 435/172.1, 172.3, 320.1; 536/23.5, 23.51; 604/51, 52, 53; 935/9, 22, 32, 33, 34, 52, 57 [IMAGE AVAILABLE
- 47. 5,652,210, Jul. 29, 1997, Soluble splice variant of the Fas (APO-1) antigen, Fas. DELTA. TM; Philip J. Barr, et al., 514/2; 435/69.1; 514/8; 530/350, 395 [IMAGE AVAILABLE]
- 48. 5,650,316, Jul. 22, 1997, Uses of triplex forming oligonucleotides for the treatment of human diseases; Bharat B. Aggarwal, et al., 435/375, 6, 7.23; 514/44; 536/24.31, 24.32, 24.33, 24.5 [IMAGE AVAILABLE]
- 49. 5,643,875, Jul. 1, 1997, Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products; Nadav Friedmann, et al., 514/12; 424/85.1, 85.2, 529, 534; 514/21, 921; 530/324, 325, 351, 820 [IMAGE AVAILABLE]
- 50. 5,641,751, Jun. 24, 1997, Tumor necrosis factor inhibitors; George A. Heavner, 514/13, 12, 14, 15, 16, 17, 18; 530/324, 325, 326, 327, 328, 329, 330 [IMAGE AVAILABLE]

=> e greene, j/in

E# FILE FREQUENCY TERM

E1 USPAT	1	GREENE,
IRWIN D/IN		
E2 USPAT	1	GREENE,
IRWIN R/IN		
E3 USPAT	0>	GREENE,
J/IN		
E4 USPAT	1	GREENE, J
JERROLD/IN		
E5 USPAT	2	GREENE,
JACK C/IN		
E6 USPAT	1	GREENE,
JACK E/IN		
E7 USPAT	2	GREENE,
JACK T/IN		
E8 USPAT	3	GREENE,
JAMES A/IN		
E9 USPAT	1	GREENE,
JAMES ALBERT/IN		
E10 USPAT	1	GREENE,
JAMES E/IN		
E11 USPAT	1	GREENE,
JAMES E JR/IN		
E12 USPAT	1	GREENE,
JAMES H/IN		

=> e greene, john/in

E# FILE	FREQUENCY	TERM
E1 USPAT	1	GREENE,
JOEL C/IN		
E2 USPAT	1	GREENE,
JOHATHAN W/IN		
E3 USPAT	2>	GREENE,
JOHN/IN		
E4 USPAT	3	GREENE,
JOHN D/IN		
E5 USPAT	1	GREENE,
JOHN F/IN		
E6 USPAT	1	GREENE,
JOHN F JR/IN		
E7 USPAT	1	GREENE,
JOHN JR/IN		
E8 USPAT	1	GREENE,
JOHN L/IN		
E9 USPAT	2	GREENE,
JOHN M/IN		
E10 USPAT	2	GREENE,
JOHN P/IN		
E11 USPAT	1	GREENE,
JONATHAN/IN		
E12 USPAT	1	GREENE,
JONATHAN A/IN		

=> s e3 or e9

2 "GREENE, JOHN"/IN
2 "GREENE, JOHN M"/IN
4 "GREENE, JOHN"/IN OR "GREENE, L3

JOHN M"/IN

=> d 1-4

- 1. 5,728,546, Mar. 17, 1998, Fibroblast growth factor 13; John M. Greene, et al., 435/69.1, 320.1, 325; 536/23.51 [IMAGE AVAILABLE]
- 2. 5,710,035, Jan. 20, 1998, Human elastase IV; John M. Greene, et al., 435/218, 69.1, 172.3, 252.3, 254.11, 320.1, 348, 358, 365, 366, 419;

536/23.2 [IMAGE AVAILABLE]

- 3. 5,502,306, Mar. 26, 1996, Electron beam inspection system and method; Dan Meisburger, et al., 250/310, 307, 397 [IMAGE AVAILABLE]
- 4. 5,299,736, Apr. 5, 1994, Air freshener device with a ceramic container and an absorbent pad; John Greene, 239/56, 34, 211 [IMAGE AVAILABLE]

=> e

E13 USPAT	10	GREENE,
JONATHAN W/IN		
E14 USPAT	1	GREENE,
JOSEPH E/IN		CDDENE
E15 USPAT	4	GREENE,
JOSEPH L/IN	1	GREENE,
E16 USPAT JOSEPH L JR/IN	1	GREENE,
E17 USPAT	1	GREENE,
JOSEPH M/IN	-	CREENE,
E18 USPAT	1	GREENE,
JOSEPH PAUL/IN		•
E19 USPAT	1	GREENE,
JOSEPH S/IN		
E20 USPAT	1	GREENE, JOY
W/IN		
E21 USPAT	1	GREENE,
JOYCE A/IN		
E22 USPAT	3	GREENE,
KAREN C/IN		60.00VB
E23 USPAT	1	GREENE,
KAREN J/IN	0	CDEENE
E24 USPAT	2	GREENE,
KATHARINE M/IN		

=> d his

E GREENE, J/IN
E GREENE, JOHN/IN
4 S E3 OR E9

L3 4 S E3 OR E9